Sudden cardiac and sudden unexpected death related to antipsychotics: A meta-analysis of observational studies.

Autor: Salvo F; University of Bordeaux, INSERM U657, Bordeaux, France.; CHU Bordeaux, Bordeaux, France., Pariente A; University of Bordeaux, INSERM U657, Bordeaux, France.; CHU Bordeaux, Bordeaux, France.; CIC Bordeaux CIC1401, Bordeaux, France., Shakir S; Drug Safety Research Unit, Southampton, Hampshire, UK., Robinson P; CIC Bordeaux CIC1401, Bordeaux, France.; ADERA, Pessac, France., Arnaud M; University of Bordeaux, INSERM U657, Bordeaux, France., Thomas S; Medical Toxicology Centre, Institute of Cellular Medicine, Newcastle University, Newcastle, UK., Raschi E; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy., Fourrier-Réglat A; University of Bordeaux, INSERM U657, Bordeaux, France.; CHU Bordeaux, Bordeaux, France., Moore N; University of Bordeaux, INSERM U657, Bordeaux, France.; CHU Bordeaux, Bordeaux, France.; CIC Bordeaux CIC1401, Bordeaux, France., Sturkenboom M; Department of Medical Informatics, Erasmus University Medical Centre, Rotterdam, Netherlands., Hazell On Behalf Of Investigators Of The Aritmo Consortium L; Drug Safety Research Unit, Southampton, Hampshire, UK.
Jazyk: angličtina
Zdroj: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2016 Mar; Vol. 99 (3), pp. 306-14. Date of Electronic Publication: 2015 Nov 20.
DOI: 10.1002/cpt.250
Abstrakt: To estimate the risk of sudden cardiac death (SCD) or sudden unexpected death (SUD) related to individual antipsychotics, a meta-analysis of observational studies was performed. Adjusted odds ratio (OR) of SCD/SUD with 95% confidence intervals (CI) were extracted and pooled; heterogeneity was studied using Q statistic and I(2) index, and its potential causes (e.g., hERG blockade potency) explored using meta-regression. Two cohort (740,306 person-years) and four case-control (2,557 cases; 17,670 controls) studies, investigating nine antipsychotics, were included. Compared with nonusers, the risk was increased for quetiapine (OR = 1.72, 95% CI: 1.33-2.23), olanzapine (OR = 2.04, 1.52-2.74), risperidone (OR = 3.04, 2.39-3.86), haloperidol (OR = 2.97, 1.59-5.54), clozapine (OR = 3.67, 1.94-6.94), and thioridazine (OR = 4.58, 2.09-10.05). Heterogeneity was found (Q = 20.0, P = 0.01; I(2) = 60.0%), and the increasing mean hERG blockade potency (P = 0.01) accounted for 43% of this. The SCD/SUD risk differed between individual antipsychotics, and mean hERG blockade potency could be an explanatory factor. This should be considered when initiating antipsychotic treatment.
(© 2015 The American Society for Clinical Pharmacology and Therapeutics.)
Databáze: MEDLINE
Externí odkaz: